ZTS supply chain intelligence for Zoetis Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Zoetis Inc. (ZTS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BANK-OF-AMERICA-N-A | BANK-OF-AMERICA-N-A | 90% | the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of America, N.A., Barclays Bank PLC (with Barclays Capital Inc. acting as agent), Go… |
| BARCLAYS-BANK-PLC | BARCLAYS-BANK-PLC | 90% | the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of America, N.A., Barclays Bank PLC (with Barclays Capital Inc. acting as agent), Go… |
| GOLDMAN-SACHS-CO-LLC | GOLDMAN-SACHS-CO-LLC | 90% | the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of America, N.A., Barclays Bank PLC (with Barclays Capital Inc. acting as agent), Go… |
| MIZUHO-MARKETS-AMERICAS-LLC | MIZUHO-MARKETS-AMERICAS-LLC | 90% | the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of America, N.A., Barclays Bank PLC (with Barclays Capital Inc. acting as agent), Go… |
| NOMURA-GLOBAL-FINANCIAL-PRODUCTS-INC | NOMURA-GLOBAL-FINANCIAL-PRODUCTS-INC | 90% | the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of America, N.A., Barclays Bank PLC (with Barclays Capital Inc. acting as agent), Go… |
| RY | Royal Bank of Canada | 90% | Reciprocal relationship from RY graph: Reciprocal relationship from ZTS graph: the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of Am… |
| RY | Royal Bank of Canada | 90% | the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of America, N.A., Barclays Bank PLC (with Barclays Capital Inc. acting as agent), Go… |
| TD | The Toronto-Dominion Bank | 90% | the Company also entered into privately negotiated capped call transactions (the “Capped Calls”) with each of Bank of America, N.A., Barclays Bank PLC (with Barclays Capital Inc. acting as agent), Go… |
| TD | The Toronto-Dominion Bank | 90% | Reciprocal relationship from TD graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from TD graph: Reciprocal relationship from ZTS graph: the Company also entered into privately n… |
| JPMORGAN-CHASE-BANK-N-A | JPMORGAN-CHASE-BANK-N-A | 80% | Zoetis and the lenders under its revolving credit facility entered into the First Waiver to Revolving Credit Agreement, dated as of December 17, 2025 (the “Waiver”), to the Revolving Credit Agreement… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from ZTS graph: lities in Tullamore (Ireland) is leased. We regularly evaluate the adequacy of our manufacturing capabilities. We are c… |
| MRK | Merck & Co., Inc. | 72% | lities in Tullamore (Ireland) is leased. We regularly evaluate the adequacy of our manufacturing capabilities. We are currently in the process of expanding these capabilities at certain existing site… |
| SPGI | S&P Global Inc. | 72% | Reciprocal relationship from SPGI graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from SPGI graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from SPGI gra… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-AGRICULTURE | USGOV-DEPARTMENT-OF-AGRICULTURE | 95% | USAspending awards from Department of Agriculture: $2,481,358 across 5 awards. 12639524F0500 DELIVERY ORDER FOR MYCOBACTERIUM BOVIS TUBERCULIN VIALS.; 12639526F0420 MYCOBACTERIUM BOVIS PURIFIED PROTE… |
| USGOV-DEPARTMENT-OF-DEFENSE | USGOV-DEPARTMENT-OF-DEFENSE | 95% | USAspending awards from Department of Defense: $2,449 across 2 awards. SPE2DS25P1684 8511596061!TEST PROFILE,CHEMIS; SPE2DS25P0090 8510962254!CARTRIDGE,BLOOD,VET | Qwen corrected direction: Explicit … |
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $69,362 across 2 awards. 75H70722P00092 RABIES VACCINES FOR OEHE WITH BASE AND FOUR OPTIONS; 75D30123P17484 VETSCAN ANALYZER | Qwen c… |
| USGOV-DEPARTMENT-OF-THE-INTERIOR | USGOV-DEPARTMENT-OF-THE-INTERIOR | 95% | USAspending awards from Department of the Interior: $35,520 across 1 awards. 140FS226P0004 NM - NEW MEXICO ESFO - CHEMICAL IMMOBILIZATION DRUG (TELAZOL) FOR MEXICAN WOLF RECOVERY PROGRAM | Qwen corre… |
| MRK | Merck & Co., Inc. | 72% | , biopharmaceutical and biological entities through new product R&D plays a critical role in our growth strategies, a significant share of our R&D investment (including regulatory functions) is focus… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from MRK graph: Reciprocal relationship from ZTS graph: , biopharmaceutical and biological enti… |
| SPGI | S&P Global Inc. | 72% | re subject to the economic, political, legal and business environments of the countries in which we do business. Our international operations could be limited or disrupted by any of the following: • … |
| SPGI | S&P Global Inc. | 72% | Reciprocal relationship from SPGI graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from SPGI graph: Reciprocal relationship from ZTS graph: re subject to the economic, political… |
| BOEHRINGER-INGELHEIM-ANIMAL-HEALTH-INC | BOEHRINGER-INGELHEIM-ANIMAL-HEALTH-INC | 62% | , biopharmaceutical and biological entities through new product R&D plays a critical role in our growth strategies, a significant share of our R&D investment (including regulatory functions) is focus… |
| BOEHRINGER-INGELHEIM-GMBH | BOEHRINGER-INGELHEIM-GMBH | 62% | , biopharmaceutical and biological entities through new product R&D plays a critical role in our growth strategies, a significant share of our R&D investment (including regulatory functions) is focus… |
| DB | Deutsche Bank Aktiengesellschaft | 62% | Reciprocal relationship from DB graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from DB graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from DB graph: Re… |
| DEUTSCHE-BANK-TRUST-COMPANY | DEUTSCHE-BANK-TRUST-COMPANY | 62% | er shares, cash or a combination thereof. The capped calls are generally intended to reduce or offset the potential dilution to our common stock upon any conversion of the convertible senior notes wi… |
| INVESTORS-SERVICE-INC | INVESTORS-SERVICE-INC | 62% | er shares, cash or a combination thereof. The capped calls are generally intended to reduce or offset the potential dilution to our common stock upon any conversion of the convertible senior notes wi… |
| MCO | Moody's Corporation | 62% | Reciprocal relationship from MCO graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from MCO graph: Reciprocal relationship from ZTS graph: Reciprocal relationship from MCO graph:… |
| PETMEDIX-LTD | PETMEDIX-LTD | 62% | be used by the U.S. Fish and Wildlife Service to help protect California condors in 2023; a conditionally licensed vaccine to help fight porcine epidemic diarrhea virus (PEDv) in the U.S.; and the fi… |
| VETERINARY-PATHOLOGY-GROUP | VETERINARY-PATHOLOGY-GROUP | 62% | of Contents Revenue by major species Three Months Ended March 31, (MILLIONS OF DOLLARS) 2026 2025 U.S. Companion animal $ 865 $ 973 Livestock 225 210 1,090 1,183 International Companion animal 654 56… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| ZTS-DEBT-7400 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| ZTS-DEBT | Debt stack $9.5B | 90% | Market cache reports total debt of $9.5B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| ZTS-OWNER-BLACKROCK-INC | Blackrock Inc. | 90% | 13F overlay lists Blackrock Inc. as top holder; 10 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| HON | Honeywell International Inc. | 100.00 | 2 | |
| FDS | FactSet Research Systems Inc. | 100.00 | 2 | |
| EVAX | Evaxion A/S | 100.00 | 2 | |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| IBIO | iBio, Inc. | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| ADAG | Adagene Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| ENLV | Enlivex Ltd. | 100.00 | 2 | |
| DB | Deutsche Bank Aktiengesellschaft | 100.00 | 1 | ['customer'] |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 | |
| IBRX | ImmunityBio, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| BKH | Black Hills Corporation | 100.00 | 2 | |
| TBPH | Theravance Biopharma, Inc. | 100.00 | 2 |